Cerebrospinal fluid levels of the macrophage-specific biomarker sCD163 are diagnostic for Lyme neuroborreliosis: an observational cohort study.

[1]  K. Blennow,et al.  Plasma neurofilament light significantly decreases following treatment in Lyme neuroborreliosis and is not associated with persistent symptoms , 2023, European journal of neurology.

[2]  R. Dessau,et al.  Discriminating between Lyme neuroborreliosis and other central nervous system infections by use of biomarkers CXCL13 and IL-6. , 2022, Ticks and tick-borne diseases.

[3]  O. Ekelund,et al.  CXCL13 in laboratory diagnosis of Lyme neuroborreliosis—the performance of the recomBead and ReaScan CXCL13 assays in human cerebrospinal fluid samples , 2021, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.

[4]  S. Linder,et al.  Molecular Mechanisms of Borrelia burgdorferi Phagocytosis and Intracellular Processing by Human Macrophages , 2021, Biology.

[5]  D. Berg,et al.  Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease , 2020, Movement disorders : official journal of the Movement Disorder Society.

[6]  A. Kjaer,et al.  64Cu-DOTATATE Positron Emission Tomography (PET) of Borrelia Burgdorferi Infection: In Vivo Imaging of Macrophages in Experimental Model of Lyme Arthritis , 2020, Diagnostics.

[7]  S. Moestrup,et al.  Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases , 2020, International journal of molecular sciences.

[8]  C. Bogdan,et al.  Comparative Analysis of the Euroimmun CXCL13 Enzyme-Linked Immunosorbent Assay and the ReaScan Lateral Flow Immunoassay for Diagnosis of Lyme Neuroborreliosis , 2020, Journal of Clinical Microbiology.

[9]  J. Halperin,et al.  Specificity and diagnostic utility of CSF CXCL13 in Lyme neuroborreliosis. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  S. Noraas,et al.  Cerebrospinal fluid cytokines and chemokines in children with Lyme neuroborreliosis; pattern and diagnostic utility. , 2020, Cytokine.

[11]  C. Lechner,et al.  Diagnostic value of cerebrospinal fluid CXCL13 for acute Lyme neuroborreliosis. A systematic review and meta-analysis. , 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  J. Hytönen,et al.  Point-of-care testing for CXCL13 in Lyme neuroborreliosis. , 2018, Diagnostic microbiology and infectious disease.

[13]  T. G. Jensen,et al.  Characteristics and Clinical Outcome of Lyme Neuroborreliosis in a High Endemic Area, 1995-2014: A Retrospective Cohort Study in Denmark. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  L. Moravcová,et al.  Prospective study on the chemokine CXCL13 in neuroborreliosis and other aseptic neuroinfections , 2016, Journal of the Neurological Sciences.

[15]  H. Pfister,et al.  Lyme neuroborreliosis—epidemiology, diagnosis and management , 2015, Nature Reviews Neurology.

[16]  H. Møller,et al.  Soluble CD163 levels are elevated in cerebrospinal fluid and serum in people with Type 2 diabetes mellitus and are associated with impaired peripheral nerve function , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[17]  H. Møller,et al.  Soluble CD163 as a Marker of Macrophage Activity in Newly Diagnosed Patients with Multiple Sclerosis , 2014, PloS one.

[18]  R. Ellis,et al.  Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection , 2013, AIDS.

[19]  G. Van den Berghe,et al.  Circulating Levels of the Shed Scavenger Receptor sCD163 and Association with Outcome of Critically Ill Patients , 2013, Journal of Clinical Immunology.

[20]  K. Herlofson,et al.  Risk factors for a non‐favorable outcome after treated European neuroborreliosis , 2013, Acta neurologica Scandinavica.

[21]  F. Strle,et al.  Lyme borreliosis , 2012, The Lancet.

[22]  H. Møller.  Soluble CD163 , 2012, Scandinavian journal of clinical and laboratory investigation.

[23]  M. Djukic,et al.  Cerebrospinal fluid findings in adults with acute Lyme neuroborreliosis , 2011, Journal of Neurology.

[24]  H. Pfister,et al.  A prospective study on the role of CXCL13 in Lyme neuroborreliosis , 2011, Neurology.

[25]  V. Fingerle,et al.  EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis , 2010, European journal of neurology.

[26]  H. Pfister,et al.  The Pathogenesis of Lyme Neuroborreliosis: From Infection to Inflammation , 2008, Molecular medicine.

[27]  K. Larsen,et al.  Diagnostic value of soluble CD163 serum levels in patients suspected of meningitis: Comparison with CRP and procalcitonin , 2007, Scandinavian journal of infectious diseases.

[28]  Ruth R. Montgomery,et al.  Recruitment of Macrophages and Polymorphonuclear Leukocytes in Lyme Carditis , 2006, Infection and Immunity.

[29]  S. Moestrup,et al.  Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163* , 2006, Critical care medicine.

[30]  R. Nadelman,et al.  Brief Communication: Hematogenous Dissemination in Early Lyme Disease , 2005, Annals of Internal Medicine.

[31]  P. Krause,et al.  Coevolution of Markers of Innate and Adaptive Immunity in Skin and Peripheral Blood of Patients with Erythema Migrans 12 , 2003, The Journal of Immunology.

[32]  S. Moestrup,et al.  Characterization of an enzyme-linked immunosorbent assay for soluble CD163 , 2002, Scandinavian journal of clinical and laboratory investigation.

[33]  P. H. Petersen,et al.  Soluble CD163: a marker molecule for monocyte/macrophage activity in disease , 2002, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[34]  R Bucks,et al.  To test or not to test? , 1996, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[35]  A. Lebech,et al.  The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985-1990. A prospective study of 187 patients with Borrelia burgdorferi specific intrathecal antibody production. , 1992, Brain : a journal of neurology.

[36]  A. Lebech,et al.  Lyme neuroborreliosis: A new sensitive diagnostic assay for intrathecal synthesis of borrelia burgdorferi–specific immunoglobulin G, A, and M , 1991, Annals of neurology.

[37]  A. Steere,et al.  Lyme borreliosis , 2016, Nature Reviews Disease Primers.

[38]  J. Meerpohl,et al.  Prevalence and spectrum of residual symptoms in Lyme neuroborreliosis after pharmacological treatment: a systematic review , 2015, Journal of Neurology.